Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Assets (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Current Assets data on record, last reported at $163.2 million in Q4 2025.

  • For Q4 2025, Current Assets fell 34.6% year-over-year to $163.2 million; the TTM value through Dec 2025 reached $163.2 million, down 34.6%, while the annual FY2025 figure was $163.2 million, 34.6% down from the prior year.
  • Current Assets reached $163.2 million in Q4 2025 per FHTX's latest filing, down from $184.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $459.6 million in Q4 2021 and bottomed at $124.0 million in Q3 2021.
  • Average Current Assets over 5 years is $268.4 million, with a median of $257.5 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 204.76% in 2022, then plummeted 34.6% in 2025.
  • A 5-year view of Current Assets shows it stood at $459.6 million in 2021, then decreased by 23.54% to $351.4 million in 2022, then tumbled by 31.65% to $240.2 million in 2023, then increased by 3.92% to $249.6 million in 2024, then tumbled by 34.6% to $163.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $163.2 million in Q4 2025, $184.1 million in Q3 2025, and $203.8 million in Q2 2025.